Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 6, 2005, Pages 1701-1705

  Ji, Min ^a   Chen, Jianyong ^a   Ding, Ke ^a   Wu, Xihan ^a   Varady, Judith ^a   Levant, Beth ^b   Wang, Shaomeng ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine receptor 3 subtype; Hexahydropyrazinoquinolines; Novel ligands

Indexed keywords

DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR AFFECTING AGENT; HEXAHYDROXYPYRAZINOQUINOLINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

EID: 14644386766     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.01.037     Document Type: Article

References (21)

1. J.N. Joyce Pharmacol. Ther. 90 2001 231 259
2. R.R. Luedtkea, and R.H. Mach Curr. Pharm. Des. 9 2003 643 671
3. S. Prasad, P. Semwal, S. Deshpande, T. Bhatia, V.L. Nimgaonkar, and B.K. Thelma J. Biosci. 27 1. Suppl 1 2002 35 52
4. M.A. Crocg, R. Mant, P. Asherson, J. Williams, Y. Hode, S. Shimohama, H. Sawada, Y. Kitamura, and T. Taniguchi Trends Mol. Med. 9 2003 360 365
5. N.D. Volkow, J.S. Fowler, and G.J. Wang Behav. Pharmacol. 13 2002 355 366
6. M. Pilla, S. Perachon, F. Sautel, F. Garrido, A. Mann, C.G. Wermuth, J.C. Schwartz, B.J. Everitt, and P. Sokoloff Nature 400 1999 371
7. 3 ligands, please see: A.E. Hackling, and H. Stark ChemBioChem 3 2002 946 961
8. M.J. Robarge, S.M. Husbands, A. Kieltyka, R. Brodbeck, A. Thurkauf, and A.H. Newman J. Med. Chem. 44 2001 3175 3186
9. L. Bettinetti, K. Schlotter, H. Hubner, and P. Gmeiner J. Med. Chem. 45 2002 4594 4597
10. A. Hackling, R. Ghosh, S. Perachon, A. Mann, H.-D. Holtje, C.G. Wermuth, J.-C. Schwartz, W. Sippl, P. Sokoloff, and H. Stark J. Med. Chem. 46 2003 3883 3899
11. M. Leopoldo, F. Berardi, N.A. Colabufo, P. De Giorgio, E. Lacivita, R. Perrone, and V. Tortorella J. Med. Chem. 45 2002 5727 5735
12. G. Campiani, S. Butini, F. Trotta, C. Fattorusso, B. Catalanotti, F. Aiello, S. Gemma, V. Nacci, E. Novellino, J.A. Stark, A. Cagnotto, E. Fumagalli, F. Carnovali, L. Cervo, and T. Mennini J. Med. Chem. 46 2003 3822 3839
13. G. Campiani, S. Butini, C. Fattorusso, B. Catalanotti, S. Gemma, V. Nacci, E. Morelli, A. Cagnotto, I. Mereghetti, T. Mennini, M. Carli, P. Minetti, M.A. Di Cesare, D. Mastroianni, N. Scafetta, B. Galletti, M.A. Stasi, M. Castorina, L. Pacifici, M. Vertechy, S.D. Serio, O. Ghirardi, O. Tinti, and P. Carminati J. Med. Chem. 47 2004 143 157
14. J. Varady, X. Wu, X. Fang, M. Ji, Z. Hu, B. Levant, and S. Wang J. Med. Chem. 46 2003 4377 4392
15. B. Levant, and D.E. Grigoriadis J. Pharmacol. Exp. Ther. 262 1992 929 935
16. G.N. Bancroft, K.S. Morgan, R.J. Flietstra, and B. Levant Neuropsychopharmacology 18 1998 305 316
17. B. Levant Characterization of dopamine receptors J. Ferkany S.J. Enna Current protocols in pharmacology 1998 John Wiley & Sons New York 1.6.1 1.6.16
18. B. Levant Pharmacol. Rev. 49 1997 231 252
19. N. Rabjohn Org. React. 24 1976 261 415
20. L.A. Vliet, N. Rodenhuis, D. Djikstra, and H. Wikstrom J. Med. Chem. 43 2000 2871 2882
21. J.M. Robarge, M.S. Husbands, A. Kieltyka, R. Brodbeck, A. Thurkauf, and H.A. Newman J. Med. Chem. 44 2001 3175 3186